Pages
Products
CAG-GFP Adeno-associated virus(AAV Serotype 8)

CAG-GFP Adeno-associated virus(AAV Serotype 8)

Cat.No. :  AAV00057Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 8 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Gene Informationn

Cat. No. AAV00057Z
Description CAG-GFP Adeno-associated virus(AAV Serotype 8) expresses eGFP under the control CAG (also known as CBA) promoter. CAG promoter is a combination of the cytomegalovirus (CMV) early enhancer element and chicken beta-actin promoter for high levels of gene expression in mammalian expression vectors.
Reporter GFP
Serotype AAV Serotype 8
Product Type Adeno-associated virus
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Gene Name
Gene Symbol
Synonyms
Gene ID
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Adeno-associated virus (AAV) is a member of the parvoviridae family. It is a type of non-enveloped, icosahedral virus that is incapable of autonomous replication. It is approximately 20-26 nm in diameter and contains a linear single-stranded DNA genome of approximately 4.7 kb. It does not generally cause disease in humans and is less likely to elicit an immune response than other viral vectors. AAV serotype 8 (AAV8) is known for its efficient transduction of liver, myocardial, and skeletal muscle tissues in a variety of animal models, including rodents and non-human primates. AAV8-based vectors have been explored in gene therapy for liver-related diseases such as hemophilia and metabolic disorders and have shown significant therapeutic benefits in preclinical models. The combination of these elements in the CAG-GFP AAV8 vector makes it a powerful tool for researchers aiming to study gene function, model disease, or develop gene therapy strategies. The CAG promoter, a combination of the Cytomegalovirus (CMV) early enhancer element and chicken beta-actin promoter, is a strong, constitutively active promoter that promotes high-level expression of genes in different tissues. GFP is a well-characterized reporter protein that fluoresces brightly green when exposed to light in the blue to UV range, making it a valuable marker for monitoring viral vector distribution and transgene expression in living cells and tissues.

Gene therapy can treat a variety of kidney diseases. However, the efficiency of gene delivery to kidney cells is low. This is partly due to the kidney's rejection of molecules larger than 50 kDa and the fact that most gene delivery vectors are megadaltons in mass. Here, researchers compared the ability of adeno-associated virus (AAV), adenovirus (Ad), and lentivirus (LV) vectors to deliver genes to kidney cells. When vectors were delivered to mice via the intravenous (IV) route, weak luciferase activity was observed in the kidneys, while significant activity was observed in the liver. When gene delivery was observed in the kidneys, expression was primarily in the glomeruli. To circumvent these limitations, vectors were injected directly into the kidneys of mice via retrograde ureteral (RU) and subcapsular (SC) injections. Small AAV vectors transduce the kidneys, but can also leak out of the organ and mediate higher levels of transduction in off-target tissues. Comparison of AAV2, 6.2, 8, and rh10 vectors by direct kidney injection showed that AAV6.2 and 8 had the highest delivery rates. Larger Ad and LV vectors transduce renal cells and mediate less off-target tissue transduction. These data demonstrate the utility of direct kidney injections to circumvent the kidney size exclusion barrier.

To assess renal transduction of a more typical reporter gene, AAV8-CAG-GFP at 2e11 GC was injected into normal FVB mice by IV, RU, and SC routes. Mice were sacrificed 4 weeks later and their kidneys and livers were analyzed for GFP by immunofluorescence staining (Figure 1). IV injection of AAV8-CAG-GFP resulted in strong, nearly ubiquitous GFP expression in the liver, but no observable GFP expression in the kidney. RU and SC injected kidney tissues showed fewer GFP-positive cells than AAV-Cre injected mT/mG mice. Interestingly, the most abundant and consistent GFP expression mediated by RU and SC injections was in the injected glomeruli and, surprisingly, in the uninjected kidneys as well. The SC-injected right kidneys also contained GFP-positive cells of tubular morphology, some of which colocalized with proximal tubule (PT) marker, lotus lectin (Figure 1). The livers of the RU- and SC-injected mice also showed significant leakage of the AAV8-CAG-GFP vector into the liver.

AAV8-CAG-GFP reporter vector mediates weaker expression than AAV8-Cre reporter vector.Figure 1. AAV8-CAG-GFP reporter vector mediates weaker expression than AAV8-Cre reporter vector. (Rubin J D, et al., 2019)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Swift delivery

I appreciate the good documentation and swift delivery, making it a seamless experience overall.

United Kingdom

12/11/2023

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER